Investigations on Binding Pattern of Kinase Inhibitors with PPARγ: Molecular Docking, Molecular Dynamic Simulations, and Free Energy Calculation Studies
Mohit Mazumder,
Prija Ponnan,
Umashankar Das,
Samudrala Gourinath,
Haseeb Ahmad Khan,
Jian Yang,
Meena Kishore Sakharkar
Affiliations
Mohit Mazumder
Structural Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India
Prija Ponnan
Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK, S7N 5C9, Canada
Umashankar Das
Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK, S7N 5C9, Canada
Samudrala Gourinath
Structural Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India
Haseeb Ahmad Khan
Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia
Jian Yang
Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK, S7N 5C9, Canada
Meena Kishore Sakharkar
Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK, S7N 5C9, Canada
Peroxisome proliferator-activated receptor gamma (PPARγ) is a potential target for the treatment of several disorders. In view of several FDA approved kinase inhibitors, in the current study, we have investigated the interaction of selected kinase inhibitors with PPARγ using computational modeling, docking, and molecular dynamics simulations (MDS). The docked conformations and MDS studies suggest that the selected KIs interact with PPARγ in the ligand binding domain (LBD) with high positive predictive values. Hence, we have for the first time shown the plausible binding of KIs in the PPARγ ligand binding site. The results obtained from these in silico investigations warrant further evaluation of kinase inhibitors as PPARγ ligands in vitro and in vivo.